Literature DB >> 11910315

Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.

Alison J Deary1, Anne L Schumann, Helen Murfet, Stephen F Haydock, Roger S-Y Foo, Morris J Brown.   

Abstract

OBJECTIVE: Hypertension guidelines recommend initial treatment with a beta-blocker or diuretic and adding the other drug where blood pressure is not controlled. We hypothesized that systematic rotation through the major classes of antihypertensive drugs would demonstrate substantial differences in the pattern of an individual patient's response, and suggest a more rational approach to choosing best treatment.
DESIGN: Thirty-four young hypertensives (age 28-55, median 47) rotated in a double-blind, Latin-square, crossover fashion through 6 weeks of treatment each with amlodipine, doxazosin, lisinopril, bisoprolol, bendrofluazide and placebo. Blood pressure was measured at each visit. 'Best' drug, defined by efficacy and tolerability, was repeated at the end.
RESULTS: Rotation doubled the number of patients reaching target blood pressure (systolic < 140 mmHg) on one drug (P = 0.03). All five drugs were represented among the 'best' drugs. In six patients, the blood pressure on 'best' drug was at least 10 mmHg lower than on any other. Response to the 'best' drug was highly correlated (r = 0.79) with its previous administration. By contrast, there were only weak correlations between responses to pairs of drugs, except for angiotensin-converting enzyme (ACE) inhibitor (A) with beta-blocker (B), and calcium blocker (C) with diuretic (D) - each r = 0.71, P < 0.005). In these young patients, the majority of patients (23/34) responded best to a drug suppressing the renin system (A and B).
CONCLUSIONS: Patients vary reproducibly in their response to initial treatment, and switching among drugs can increase the efficacy of monotherapy. The results support an AB/CD scheme for choosing therapy, in which the first drug is taken from one of these pairs, and uncontrolled patients switch to one of the other pair.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11910315     DOI: 10.1097/00004872-200204000-00037

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  21 in total

Review 1.  Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index.

Authors:  Charlotte H Manisty; Alun D Hughes
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 2.  Treatment of resistant hypertension.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

3.  Organisational factors in relation to control of blood pressure: an observational study.

Authors:  Melanie Inkster; Alan Montgomery; Peter Donnan; Tom MacDonald; Frank Sullivan; Tom Fahey
Journal:  Br J Gen Pract       Date:  2005-12       Impact factor: 5.386

Review 4.  Molecular and clinical investigations in patients with low-renin hypertension.

Authors:  Isla S Mackenzie; Morris J Brown
Journal:  Clin Exp Nephrol       Date:  2008-08-15       Impact factor: 2.801

5.  Predicting changes in hypertension control using electronic health records from a chronic disease management program.

Authors:  Jimeng Sun; Candace D McNaughton; Ping Zhang; Adam Perer; Aris Gkoulalas-Divanis; Joshua C Denny; Jacqueline Kirby; Thomas Lasko; Alexander Saip; Bradley A Malin
Journal:  J Am Med Inform Assoc       Date:  2013-09-17       Impact factor: 4.497

6.  Blood pressure control and acceptability of perindopril and its fixed dose combinations with amlodipine or indapamide, in younger patients with hypertension.

Authors:  Sandeep Bansal; D K Chauhan; D Ramesh; Shahid Barmare; Shaibal Chakraborty
Journal:  Indian Heart J       Date:  2014-11-28

7.  Increasing the Precision of Hypertension Treatment Through Personalized Trials: a Pilot Study.

Authors:  Ian M Kronish; Ying Kuen Cheung; Daichi Shimbo; Jacob Julian; Benjamin Gallagher; Faith Parsons; Karina W Davidson
Journal:  J Gen Intern Med       Date:  2019-03-11       Impact factor: 5.128

Review 8.  Individualizing antihypertensive combination therapies: clinical and hemodynamic considerations.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

Review 9.  Renin: friend or foe?

Authors:  Morris J Brown
Journal:  Heart       Date:  2007-05-08       Impact factor: 5.994

10.  Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies.

Authors:  Gul Yener; Sinan Aran; Mithat Bahceci; Kurtulus Ozdemir; Fusun Gultekin; Wing Lowe
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.